Decision review · 11 Sep 2026
Three options, one recommendation, and the number that would change our minds.
Press → or space to advance · N for the presenter window · ? for all keys
Where we are
Source: Finance DW, extracted 31 Aug 2026. September excluded as an open period.
The pattern
Contribution margin, %, closed periods only.
Diagnosis
Options
| Option | In-quarter cost | If we are right | If we are wrong |
|---|---|---|---|
| Fund recovery now | €1.8m | Region stabilises by Q1 | €1.8m into a structural decline |
| Reallocate to North and Central | €0.3m | Contribution up ~€0.6m | Exit a market we could have kept |
| Diagnose first, decide in November | €0.1m | Decision made on evidence | Six weeks of continued bleed (~€0.2m) |
Costs are directly attributable only; no overhead allocation.
Recommendation
Six weeks of bleed costs roughly €0.2m. Choosing wrong between the other two options costs between €0.6m and €1.8m. The diagnostic is cheap relative to the decision it informs.
What would change our minds
That threshold is where the recovery case stops clearing its own cost of capital on any reasonable price assumption. It is measurable on 3 November.
Stating the falsifier in advance is what separates a recommendation from a preference.